Mensing Doesn't Nix Generic-Fosamax Claims, 3rd Circ. Told

Law360, New York (September 24, 2013, 2:38 PM EDT) -- A federal judge wrongfully used the U.S. Supreme Court's Pliva Inc. v. Mensing ruling to preempt design defect claims against generic-drug makers in multidistrict litigation over the safety of Merck & Co.'s bone drug Fosamax, according to a briefing filed Monday with the Third Circuit.

The plaintiffs told the appeals court that there is “no logical basis” to conclude the Supreme Court’s Mensing decision — which found that failure-to-warn claims against generic companies are preempted since they must match their labeling to brand-name labeling under federal...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.